

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

ADDITIONAL RESUMPTION GUIDANCE

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong).

References are made to the Company’s announcements: —

- (i) the announcement dated 15 July 2015 in relation to the resumption conditions imposed by the Stock Exchange; and
- (ii) the announcements dated 10 August 2018, 15 November 2018 and 11 February 2019 respectively in relation to updates on trading suspension.

On 11 April 2019, the Stock Exchange issued a letter to the Company informing that the Stock Exchange has considered it appropriate to require the Company, as an additional resumption guidance, to demonstrate a sufficient level of operations or assets under Rule 13.24 to warrant the continued listing the Company’s shares.

For the avoidance of doubt, the Company is still subject to all the other resumption conditions set out in the announcement dated 15 July 2015.

The Company will inform the shareholders of further updates on trading suspension.

** For identification purpose only*

Trading in the shares of the Company will remain suspended until further notice.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 18 April 2019

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors and (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Ms. Fan Stephanie Winnie and Mr. Cheung Chi Ming as independent non-executive Directors.